JPMorgan sees “bullish setup” for 2026 as markets eye Fed pivot and sector rotation

JPMorgan forecasts a constructive setup for equities in 2026 as the macro balance shifts toward growth-friendly policy: markets have largely priced a December Fed cut, limiting immediate upside and raising short-term profit‑taking risk, but cheaper oil, easing wage growth and potential tariff relief could anchor yields and keep central banks easing through 2026. The bank highlights Europe-specific tailwinds — fading trade uncertainty, a better China outlook, stepped-up Eurozone fiscal spending — plus continued US AI-driven investment, and expects sector rotation away from 2025 winners (defence, utilities, insurers) toward exporters (autos and major European consumer/luxury exporters), healthcare and semiconductors, with banks remaining resilient.

Analysis

Market structure: A Fed pivot priced for December removes immediate upside from a rates surprise and increases near-term profit-taking risk, but a sustained easing cycle into 2026 would compress term premia (10y yield down 50–100bp possible) and re-rate cyclicals — exporters (ASML, NVS, NVO, AZN, SAP) and semiconductors gain pricing power from AI capex while defensives (utilities, insurers, defence) face multiple compression. Competitive dynamics: AI-driven US capex concentrates share gains in high-end equipment suppliers (ASML) and fab-dependent chipmakers, tightening supply chains and enabling 5–15% pricing power increases for constrained nodes; pharma/luxury exporters benefit from margin tailwinds via cheaper energy and easing wages. Cross-asset: anchored yields favor equities, steepening risk supports banks (JPM) and credit spreads tightening; EUR likely to appreciate on Eurozone fiscal surprise and China reopening (EURUSD +2–5% scenario), compressing exporter FX-adjusted gains; lower oil depresses energy and boosts consumer discretionary. Risks & timing: immediate (days) — ‘‘travel and arrive’’ profit-taking around the Fed; short-term (weeks–months) — rotation into laggards if 10y slips below 3.5%; long-term (quarters) — earnings catch-up for semis/healthcare. Tail risks include China hard-landing, OPEC+ shock, or regulatory action (chip export controls/ASML licensing, pharma pricing) that could wipe 20–40% of expected gains. Hidden dependencies: AI capex is binary on enterprise demand and US policy; fiscal stimulus in Europe could flip rate trajectory and hurt growth multiple. Catalysts to monitor: Fed statements (real yield guidance), Eurozone fiscal package timing, China PMI, ASML order flow, leading-capex announcements (within 30–90 days).

Key Decisions for Investors

• Establish a 1.5–3.0% long position in ASML (ticker ASML) via a 6–9 month call spread sized to target 20–40% upside (buy ITM call, sell higher-strike call) to capture AI-driven capex upside while limiting downside to ~5–7% of portfolio value; enter on a <=3% post-Fed pullback, set stop-loss if spread mark declines 40% from entry.
• Build a 1–2% thematic healthcare/exporter allocation: long NVO (0.8–1.2%) and NVS (0.5–0.8%) vs. a 0.8–1.0% short in SNY (pair trade) to capture branded pharma secular growth and margin tailwinds while hedging region/regulatory risk; target 6–12 month horizon, take profits at +25–30% or if EURUSD strengthens >4% from entry.
• Reduce cyclical defensives: trim utilities/insurers exposure by 40–60% (or initiate 0.5–1.0% short via XLU for US utilities) within 1–3 trading days post-Fed to avoid the expected year-end profit-taking; redeploy proceeds into ASML/NVO/NVS and bank exposure (add 0.5–1.0% JPM long) if 10y yield falls below 3.75%.
• Use options tactically around macro catalysts: sell overpriced near-term SPX volatility (sell 7–21 day ATM straddle) only after realized vol settles post-Fed, and buy 6–9 month protective puts (5–8% OTM) on exporter-heavy baskets (e.g., pan-European ETF or SAP) if EURUSD moves unfavorably >3% — allocate <1% notional to hedge FX/regulatory tail risks.